These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32555445)

  • 1. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
    Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
    Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoengineered targeting strategy for cancer immunotherapy.
    Yin WM; Li YW; Gu YQ; Luo M
    Acta Pharmacol Sin; 2020 Jul; 41(7):902-910. PubMed ID: 32398683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing cancer immunotherapy with nanomedicine.
    Irvine DJ; Dane EL
    Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
    Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
    Front Immunol; 2020; 11():601497. PubMed ID: 33408716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.
    Naik A; Monjazeb AM; Decock J
    Front Immunol; 2019; 10():1940. PubMed ID: 31475003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Nanomedicines in an Evolving Oncology Landscape.
    Guo P; Huang J; Moses MA
    Trends Pharmacol Sci; 2020 Oct; 41(10):730-742. PubMed ID: 32873407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy.
    Zhang Y; Ma S; Liu X; Xu Y; Zhao J; Si X; Li H; Huang Z; Wang Z; Tang Z; Song W; Chen X
    Adv Mater; 2021 Feb; 33(7):e2007293. PubMed ID: 33448050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
    Cyprian FS; Akhtar S; Gatalica Z; Vranic S
    Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved cancer immunotherapy strategies by nanomedicine.
    Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy.
    Dogheim GM; El Feel NE; Abd El-Maksod EA; Amer SS; El-Gizawy SA; Abd Elhamid AS; Elzoghby AO
    Drug Discov Today; 2024 Mar; 29(3):103905. PubMed ID: 38295898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.